Evidence map›Paper›PMID 28052137›Full record

ArticlePLoS pathogens2017

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.

Nicole A Doria-Rose, Han R Altae-Tran, Ryan S Roark, Stephen D Schmidt, Matthew S Sutton, Mark K Louder, Gwo-Yu Chuang, Robert T Bailer, Valerie Cortez, Rui Kong and 14 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Nicole A Doria-RoseVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Han R Altae-TranVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Ryan S RoarkVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Stephen D SchmidtVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Matthew S SuttonVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Mark K LouderVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Gwo-Yu ChuangVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Robert T BailerVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Valerie CortezHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0002-1267-5596
Rui KongVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0003-1779-5885
Krisha McKeeVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Sijy O'DellVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Felicia WangVanderbilt Vaccine Center, Vanderbilt University, Nashville, TN, United States of America.
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-4986-2133
James M BinleySan Diego Biomedical Research Institute, San Diego, CA, United States of America.
Mark ConnorsHIV-Specific Immunity Section, National Institutes of Health, Bethesda, MD, United States of America.
Barton F HaynesDuke University Human Vaccine Institute, Durham, NC, United States of America.
Malcolm A MartinLaboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0002-6845-9905
David C MontefioriDuke University Human Vaccine Institute, Durham, NC, United States of America.
Lynn MorrisCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Julie OverbaughHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Peter D KwongVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
John R MascolaVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
Ivelin S GeorgievVaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
National Institutes of Health · USDuke University · USCentre for the AIDS Programme of Research in South Africa · ZAFred Hutch Cancer Center · USSan Diego Biomedical Research Institute · USUniversity of the Witwatersrand · ZAUniversity of Washington · USVanderbilt University · US

Funding

Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
The Biology of HIV InfectionsZIAAI001213 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2016 to 2025
$23.7M
Mechanisms of Effective Humoral Immune Responses to HIV-1ZIAAI001090 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$14.8M
EARLY INFECTION IN WOMEN EXPOSED MUCOSALLY TO HIV-1R37AI038518 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 1999 to 2019
$12.9M
Pure and Authentic HIV-1 Env ImmunogensR01AI093278 · NIAID · TORREY PINES INST FOR MOLECULAR STUDIES · PI BINLEY, JAMES M · 2011 to 2024
$11.6M
Determination of the Neutralization Specificity in Broadly Neutralizing HIV SeraZIAAI005089 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$9.6M
Measurement of HIV Neutralization Using Quantitative AssaysZIAAI005010 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$7.6M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)KL2TR000446 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$2.8M
Computational Algorithms, Methods, and Tools for Structure-Based Vaccine DesignZICAI005113 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KWONG, PETER D · 2010 to 2019
$2.5M
NCATS NIH HHS KL2 TR000446NIAID NIH HHS R01 AI093278NIAID NIH HHS R37 AI038518
6 · The paper itself

Abstract

Computational neutralization fingerprinting, NFP, is an efficient and accurate method for predicting the epitope specificities of polyclonal antibody responses to HIV-1 infection. Here, we present next-generation NFP algorithms that substantially improve prediction accuracy for individual donors and enable serologic analysis for entire cohorts. Specifically, we developed algorithms for: (a) selection of optimized virus neutralization panels for NFP analysis, (b) estimation of NFP prediction confidence for each serum sample, and (c) identification of sera with potentially novel epitope specificities. At the individual donor level, the next-generation NFP algorithms particularly improved the ability to detect multiple epitope specificities in a sample, as confirmed both for computationally simulated polyclonal sera and for samples from HIV-infected donors. Specifically, the next-generation NFP algorithms detected multiple specificities in twice as many samples of simulated sera. Further, unlike the first-generation NFP, the new algorithms were able to detect both of the previously confirmed antibody specificities, VRC01-like and PG9-like, in donor CHAVI 0219. At the cohort level, analysis of ~150 broadly neutralizing HIV-infected donor samples suggested a potential connection between clade of infection and types of elicited epitope specificities. Most notably, while 10E8-like antibodies were observed in infections from different clades, an enrichment of such antibodies was predicted for clade B samples. Ultimately, such large-scale analyses of antibody responses to HIV-1 infection can help guide the design of epitope-specific vaccines that are tailored to take into account the prevalence of infecting clades within a specific geographic region. Overall, the next-generation NFP technology will be an important tool for the analysis of broadly neutralizing polyclonal antibody responses against HIV-1.

Indexed as

AIDS VaccinesAlgorithmsAntibody FormationAntibody SpecificityCohort StudiesComputer SimulationEpitope MappingEpitopesHIV-1HIV AntibodiesHIV InfectionsHumansNeutralization TestsAIDS VaccinesEpitopesHIV Antibodies

Identifiers

PMID28052137
PMCPMC5241146
OpenAlexW2570553572

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.